Philadelphia Chromosome Positive Recruiting Phase 2 Trials for Cytarabine (DB00987)

Also known as: Philadelphia chromosome positive

IndicationStatusPhase
DBCOND0046287 (Philadelphia Chromosome Positive)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03263572Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic LeukemiaTreatment
NCT03147612Low-Intensity Chemotherapy and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic LeukemiaTreatment
NCT01424982Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic LeukemiaTreatment
NCT03589729Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood CancersSupportive Care